Articles from Purna Pharmaceuticals

Puurs, Belgium, June 04, 2026 (GLOBE NEWSWIRE) -- Purna Pharmaceuticals (“Purna”), a specialty contract development and manufacturing organization and portfolio company of Ampersand Capital Partners (“Ampersand”), today announced the appointment of Marc Verbruggen as Managing Director, effective June 1, 2026. Purna specializes in the development, manufacture and supply of liquid and semi-solid pharmaceutical products.   Dr. Stefan Beyer, who is an Ampersand Executive Advisor and has served as Purna’s Interim Managing Director, has joined the company’s Board of Directors as its Chairman.